ArticleMicrobiology spectrum2026
Innate host defense lysozyme may help control
Patrick M Schlievert, Samuel H Kilgore, Evgeny Berdyshev, Michael Nodzenski, Gloria David, Takeshi Yoshida, Lisa A Beck, Donald Y M Leung
Abstract read
In one paragraphArticle in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Patrick M SchlievertDepartment of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.ORCID 0000-0001-8314-9369 Samuel H KilgoreDepartment of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
Evgeny BerdyshevDepartment of Medicine, National Jewish Health, Denver, Colorado, USA.
Michael NodzenskiRho, Inc., Durham, North Carolina, USA.
Gloria DavidRho, Inc., Durham, North Carolina, USA.
Takeshi YoshidaDepartment of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.
Lisa A BeckDepartment of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0000-0002-8452-667X Donald Y M LeungDepartment of Pediatrics, National Jewish Health, Denver, Colorado, USA.
Funding
RhoFED AA-SCCCU01AI178772 · NIAID · RHO FEDERAL SYSTEMS DIVISION, INC. · PI Gloria David, Cynthia M Visness · 2023 to 2026
$37.2MTargeted Microbiome Transplant in Atopic DermatitisU19AI117673 · NIAID · NATIONAL JEWISH HEALTH · PI GEHA, RAIF SALIM · 2015 to 2019
$30.6MBiomarker Identification, Viral Susceptibility and Management in S. aureus Colonized AD PatientsU01AI152011 · NIAID · UNIVERSITY OF ROCHESTER · PI Lisa Ann Beck · 2020 to 2026
$3.2MNIAID NIH HHS U01 AI152011NIAID NIH HHS U01 AI178772NIAID NIH HHS U19 AI117673NIH HHS U01AI152011NIH HHS U01AI178772NIH HHS U19AI117673NIH HHS UMAI151958
6 · The paper itselfAbstract
Atopic dermatitis (AD) is a chronic pruritic skin condition characterized by lesions associated with colonization and infection by IMPORTANCE:
Indexed as
Dermatitis, AtopicImmunity, InnateMuramidaseStaphylococcal InfectionsStaphylococcus aureusAntibodies, Monoclonal, HumanizedFemaleHumansAntibodies, Monoclonal, HumanizeddupilumabMuramidaseatopic dermatitislysozymeStaphylococcus aureus
Identifiers
PMID42578672
PMCPMC13532329
What OpenQuestion holds
Textmetadata
Read underepoch 390